Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
The Company’s common stock will begin trading on a post-split basis at the opening of trading on October reverse stock split, every four shares of issued and outstanding common stock will be converted to one post-reverse (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Completes Patient Enrollment for Phase 2a Alzheimer's Trial Ahead of Schedule
It started in January 2015 and all the 32 patients, most who are also taking donepezil, have initiated About Alzheimer’s Disease Today, Alzheimer’s disease remains the largest unmet medical need in neurology More than 25 million people are currently diagnosed with Alzheimer’s, with the associated cost of care (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex to Present at 2015 Ladenburg Thalmann Healthcare Conference
A live audio webcast of the presentation will be available under the conference website at http://wsw.com (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Reports Fiscal Third Quarter 2015 Financial Results
Alzheimer’s is the most widely recognized neurodegenerative disease associated with the aggregation of factor since seizures cause neuro-cognitive impairments, which can be worsened by current epilepsy medications (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Reports Fiscal Third Quarter 2015 Financial Results
Our work with MJFF underscores our unwavering commitment to delivering new medications for neurological It is the second most common neurological disorder and approximately one million people in the United As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- ANAVEX 2-73 showing Early Evidence of Improving Cognition in Patients with Alzheimer's Disease
consistent with the Phase 1 data; additional clinical data of the trial will be presented at future medical It started in January 2015 and the first 12 patients, most who are also taking donepezil, have completed About Alzheimer’s Disease Today, Alzheimer’s disease remains the largest unmet medical need in neurology More than 25 million people are currently diagnosed with Alzheimer’s, with the associated cost of care projected in any of such statements due to various factors, including the risks set forth in the Company’s most
- Anavex to Present Inintial Clinical Data from the Phase 2a Clinical Trial of ANAVEX 2-73 at AAIC
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Strengthens Board of Directors
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, Hallmark of Alzheimer's
Alzheimer’s is the most widely recognized neurodegenerative disease associated with the aggregation of (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Releases Promising Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference
factor since seizures cause neuro-cognitive impairments, which can be worsened by current epilepsy medications About Epilepsy Epilepsy is the most common serious neurological disorder, affecting people of all ages (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Reports Fiscal Second Quarter 2015 Financial Results
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
